A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

Hims & Hers achieved 136% YoY subscriber growth and unveiled ambitious 2030 goals. Discover how precision medicine drives ...

Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk's diabetes drug Ozempic and Wegovy, in May of 2024. The company has largely had to stop offering the ...

That month, the company released its Q4 results and announced that it would stop offering compounded semaglutide, the active ingredient used in Wegovy and similar GLP-1 weight loss drugs ...

In recent weeks, changes have occurred in the weight-loss landscape, including the ending of the two-year-long shortage of Ozempic and Wegovy. This means that compounding pharmacies ... I’ve seen many ...

A year ago, demand for GLP-1 drugs like Wegovy far outstripped supply, prompting many patients to turn to compounded versions made by smaller pharmacies. These compounded semaglutide products ...

PHOENIX - Compounding pharmacies will no longer be allowed to create semaglutide injections, a generic and cheaper version of Ozempic and Wegovy. This comes after a judge rejected a bid by these ...